MarginsXMarginsX
Home › Markets › Health Care › BTTC

Black Titan Corporation (BTTC)

BTTC trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.2873
-9.20% on the day
Market cap
$4.3M
Nano cap
Revenue · 2026
$2.2M
-18.8% on 2025
Net income · 2026
-$5.8M
-268.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2026-07-31, https://www.sec.gov/Archives/edgar/data/2034400/000149315226050502/0001493152-26-050502-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2026-07-31.

Profile

FieldValue
TickerBTTC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryMalaysia
IPO yearNot reported by the screener
SEC CIK0002034400
SEC industry codeServices-Computer Programming Services

Financials · 2026

LineValue
Revenue$2.2M
Net income-$5.8M
Operating income-$5.7M
Net margin-268.1%
Operating margin-262.1%
Revenue growth-18.8%
Cash$2.9M
Total assets$7.6M
P/E (computed)Net income was not positive
P/S (computed)2.0×

Warning signs

Cash runway
6.8 months
$2.9M cash at July 31, 2026
Share count, 1 year
+94.2%
2025-11-28 to 2026-11-02
Going-concern doubt
Yes
20-F filed November 6, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern."
20-F 2026-11-06
Cash and burn$2.9M cash; operating cash flow -$1.3M a quarter.Report 2026-07-31
Shares outstanding14,996,962 (2026-11-02); 7,723,620 a year earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGuangdong Prouden CPAs GP, Guangzhou, ChinaPCAOB Form AP 2026-11-11
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-07-31
$2.2M-$5.8M-$5.0M$2.9M$490K$2.2M20-F 2026-11-06
FY 2025
2025-07-31
$2.7M$210K$394K$575K$20K$2.7M20-F 2026-11-06
FY 2024
2024-07-31
$2.1M$153K$192K$684KNo debt tags$2.1M20-F 2026-11-06

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-05-18
Latest annual report20-F2026-11-06
Latest quarterly / interim6-K2026-11-13

Source: SEC EDGAR submissions feed, 84 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+12.9%
1 month-27.9%
3 months-50.3%
Year to date-81.1%
1 year-90.2%
From 52-week high-92.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CRISCuris Inc.$0.4358-2.07%$4.1M
LIMNLiminatus Pharma Inc.$2.97-0.67%$4.0M
CELZCreative Medical Technology Holdings Inc.$0.5201-1.51%$4.0M
AIMAIM ImmunoTech Inc.$0.1310-8.77%$5.2M
SNTISenti Biosciences Holdings Inc.$0.1360-2.86%$5.2M
VIVSVivoSim Labs Inc.$0.1237-2.68%$2.5M
CLDICalidi Biotherapeutics Inc.$0.6023-3.15%$2.2M
INABIN8bio Inc.$0.8160-0.49%$8.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier